Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | MEP1A | Q16819 | 1/20 | 0.46 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | DAO | P14920 | 1/20 | 0.43 |
| ▸ | IDH1 | O75874 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.42 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.42 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30646949 | 1.00 | GLA (0.51) | GLAMEP1AMEP1BCYP19A1CYP11B1 | |
| SCHEMBL4060950 | 0.89 | CLK4 (0.46) | GLA | |
| SCHEMBL2556190 | 0.83 | GLA (0.47) | GLAMEP1AMEP1BCYP19A1CYP11B1 | |
| SCHEMBL28879916 | 0.82 | GLA (0.46) | GLAMEP1AMEP1BCYP19A1CYP11B1 | |
| SCHEMBL2162055 | 0.82 | GLA (0.46) | GLAMEP1AMEP1BCYP19A1CYP11B1 | |
| SCHEMBL28728197 | 0.82 | GLA (0.46) | GLAMEP1AMEP1BCYP19A1CYP11B1 | |
| SCHEMBL7776828 | 0.80 | CA12 (0.43) | GLALMNAFFAR1 | |
| SCHEMBL16167007 | 0.79 | GLA (0.47) | GLAMEP1AMEP1BCYP19A1CYP11B1 | |
| SCHEMBL8668592 | 0.79 | FBP1 (0.45) | GLAMEP1AMEP1BCYP19A1CYP11B1 | |
| SCHEMBL7377009 | 0.79 | ENPP2 (0.46) | GLAMEP1AMEP1BCYP19A1CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4294800-B1 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS INC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260055083-A1 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS INC (US) | 2026-02-26 | — | — | US | disclosed |
| EP-4573077-A1 | APOL1 INHIBITORS AND METHODS OF USE | Maze Therapeutics, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| WO-2024249252-A1 | METHODS OF USING APOL1 INHIBITORS | MAZE THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| US-20240316038-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2024-09-26 | — | — | US | disclosed |
| WO-2024040235-A1 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
| EP-4294800-A1 | APOL1 INHIBITORS AND METHODS OF USE | Maze Therapeutics, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| CN-114956933-A | Marker containing isotope oxygen atom and preparation method and application thereof | 清华大学 | 2022-08-30 | — | — | CN | disclosed |
| WO-2022178315-A1 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2022-08-25 | — | — | WO | disclosed |
| CN-113214054-A | Synthesis method of phenylacetaldehyde derivative | 合肥华纳生物医药科技有限公司 | 2021-08-06 | — | — | CN | disclosed |
| US-20050261299-A1 | 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors | IN2GEN CO., LTD. (KR) | 2005-11-24 | — | — | US | disclosed |
| WO-2005103028-A1 | 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS ALK5 AND/OR ALK4 INHIBITORS | IN2GEN CO., LTD (KR) | 2005-11-03 | — | — | WO | disclosed |
| US-6956046-B2 | 4-hydroxypiperidine derivatives having analgesic activity | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2005-10-18 | — | — | US | disclosed |
| US-20040176410-A1 | 4-hydroxpiperdine derivative with analgetic activity | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2004-09-09 | — | — | US | disclosed |
| EP-1391452-A1 | 4-HYDROXPIPERIDINE DERIVATIVE WITH ANALGETIC ACTIVITY | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2004-02-25 | — | — | EP | disclosed |
| EP-1346994-A1 | CHOLESTEROL BIOSYNTHESIS INHIBITORS CONTAINING AS THE ACTIVE INGREDIENT TRICYCLIC SPIRO COMPOUNDS | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2003-09-24 | — | — | EP | disclosed |
| CN-1283187-A | Novel dipydropyridine derivative | AJINOMOTO KK (JP) | 2001-02-07 | — | — | CN | disclosed |
| EP-1071669-A1 | BICYCLIC COMPOUNDS HAVING AN ANTI-THROMBITIC EFFECT | Boehringer Ingelheim Pharma KG (DE) | 2001-01-31 | — | — | EP | disclosed |
| CN-1252070-A | 5,7-disubstituted 4-aminopyrido [2,3,-d] pyrimidine compounds and their use as adenosine kinase inhibitors | ABBOTT LAB (US) | 2000-05-03 | — | — | CN | disclosed |
| WO-1999054313-A1 | BICYCLIC COMPOUNDS HAVING AN ANTI-THROMBITIC EFFECT | BOEHRINGER INGELHEIM PHARMA KG (DE) | 1999-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261299-A1 | 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors | ACVR1, ACVRL1, ACVR1B | GLA 2027/4885MEP1A 556/4885MEP1B 254/4885 |
| US-20040176410-A1 | 4-hydroxpiperdine derivative with analgetic activity | HNMT, HDAC1, HDAC3 | GLA 3038/4885MEP1A 3873/4885MEP1B 3198/4885 |
| US-20260055083-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, LDLR, APOB | GLA 437/4885MEP1A 2747/4885MEP1B 1639/4885 |
| US-20240316038-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, SAAL1, APOB | GLA 313/4885MEP1A 3055/4885MEP1B 2541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.